Monte Rosa Therapeutics CEO sells 9,500 shares

Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported an open-market sale of 9,500 shares of Common Stock on July 16, 2026.

Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported an open-market sale of 9,500 shares of Common Stock on July 16, 2026. The shares were sold at a weighted average price of $23.1809 per share, with individual trades between $23.18 and $23.23. Following this transaction, Warmuth directly holds 585,038 shares of Monte Rosa Therapeutics. The transaction is not indicated as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 9,500 shares

Net Sell 1 txn

Insider Warmuth Markus

Role President & CEO

Sold 9,500 shs ($220K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	9,500	$23.1809	$220K

Holdings After Transaction: Common Stock — 585,038 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 9500 shares Weighted average sale price: $23.1809 per share Sale price range low: $23.18 per share +2 more

5 metrics

Shares sold 9500 shares Common Stock sold on July 16, 2026

Weighted average sale price $23.1809 per share Weighted average price for the 9,500 shares sold

Sale price range low $23.18 per share Lowest price among multiple sale transactions

Sale price range high $23.23 per share Highest price among multiple sale transactions

Shares held after transaction 585038 shares Direct ownership of Common Stock following the sale

Key Terms

weighted average price, open market or private transaction, Common Stock

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Sale in open market or private transaction"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock sale did Monte Rosa Therapeutics (GLUE) report?

Monte Rosa Therapeutics reported that President & CEO Markus Warmuth sold 9,500 shares of Common Stock on July 16, 2026 at a weighted average price of $23.1809 per share in open-market transactions.

At what prices did the GLUE CEO sell shares in this Form 4?

The CEO’s sale had a weighted average price of $23.1809 per share, with individual trades executed at prices ranging from $23.18 to $23.23, according to the Form 4 footnote.

How many Monte Rosa Therapeutics (GLUE) shares does the CEO hold after the sale?

After selling 9,500 shares, President & CEO Markus Warmuth directly holds 585,038 shares of Monte Rosa Therapeutics Common Stock, as reported in the Form 4’s post-transaction ownership column.

Was the Monte Rosa Therapeutics (GLUE) insider sale under a Rule 10b5-1 plan?

The Form 4 indicates the transaction was not carried out under a Rule 10b5-1 trading plan, as the related checkbox for such a plan is shown as unchecked in the filing data.

What type of transaction is reported in the Monte Rosa Therapeutics (GLUE) Form 4?

The filing reports a sale of Common Stock coded as an “S” transaction, described as a sale in an open market or private transaction, with direct ownership reported after the trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warmuth Markus

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		S		9,500	D	$23.1809(1)	585,038	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Phil Nickson, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)